By identifying an upregulation of catalase (CAT) in IBD (Figure S1), “catalytic medicine” inspired us to deliver CAT substrates to produce oxygen, ultimately forming pathologically catalyzed PDA physical coatings, which are anti-inflammatory and biocompatible. The gene discussed is CAT; the disease is inflammatory bowel disease.